Copenhagen-based biotech company Draupnir Bio secured €12M in seed funding to develop its preclinical pipeline of oral, small molecule protein degraders. These degraders target extracellular disease-causing proteins, leveraging lysosomal machinery. Led by CEO Andrew Hotchkiss, Draupnir Bio focuses on advancing targeted protein degradation, spun out from Aarhus University and the Max-Planck Society.
Latest News
- ELIVAAS Raises $5 Million in Series A Funding to Expand Luxury Vacation Rentals
- OYO to Acquire G6 Hospitality for $525 Million in All-Cash Deal
- Infibeam Avenues Set to Launch RediffPay, Joining UPI Market
- Momos Raises $10M to Expand AI-Powered Customer Platform
- Epica International Secures $18M to Boost Medical Imaging and Robotics
Read More
ELIVAAS Raises $5 Million in Series A Funding to Expand Luxury Vacation Rentals
ELIVAAS, a Gurugram-based vacation home rental platform, has raised $5 million in its Series A funding round. The
By Fundingraised
OYO to Acquire G6 Hospitality for $525 Million in All-Cash Deal
OYO, the Indian-based hospitality giant, has announced a significant move to acquire G6 Hospitality, the company behind the
Infibeam Avenues Set to Launch RediffPay, Joining UPI Market
Infibeam Avenues Limited is set to launch a new payment app, RediffPay, which will place the company in